References
- Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348, 1309–1321 (2003).
- Rossignol P, Ménard J, Fay R et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J. Am. Coll. Cardiol.58, 1958–1966 (2011).
- Pitt B, Williams G, Remme W et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival study. Cardiovasc. Drugs Ther.15, 79–87 (2001).
- Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure. Cochrane Database Syst. Rev. doi:10.1002/14651858.CD003838.pub2 (2009) (Epub ahead of print).
- Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol.49, 675–683 (2007).
- Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation122, 265–272 (2010).
- Pitt B, Bakris G, Ruilope LM et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study (EPHESUS). Circulation118, 1643–1650 (2008).
- Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol.46, 425–431 (2005).
- Pitt B, Zannad F, Remme W et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341, 709–717 (1999).
- Zannad F, McMurray JJV, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med.364, 11–21 (2011).
- Iraqi W, Rossignol P, Angioi M et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study (EPHESUS). Circulation119, 2471–2479 (2009).
- Rousseau MF, Gurné O, Duprez D et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J. Am. Coll. Cardiol.40(9), 1596–1601 (2002).
- Enomoto S, Yoshiyama M, Omura T et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodeling after myocardial infarction. Heart91(12), 1595–1600 (2005).